Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for Dianthus Therapeutics (DNTH) over the last 5 years, with Sep 2025 value amounting to $2.3 million.

  • Dianthus Therapeutics' Amortizatization of Intangibles fell 1.28% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 111.27%. This contributed to the annual value of $6.0 million for FY2024, which is 322.91% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Amortizatization of Intangibles stood at $2.3 million for Q3 2025, which was up 110.47% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Amortizatization of Intangibles ranged from a high of $2.7 million in Q4 2024 and a low of -$115,000 during Q1 2022.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $527,000 (2023), whereas its average is $1.2 million.
  • Per our database at Business Quant, Dianthus Therapeutics' Amortizatization of Intangibles dropped by 23.61% in 2023 and then soared by 609.39% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $402,000 in 2022, then soared by 31.09% to $527,000 in 2023, then skyrocketed by 419.35% to $2.7 million in 2024, then declined by 1.28% to $2.3 million in 2025.
  • Its Amortizatization of Intangibles was $2.3 million in Q3 2025, compared to $1.1 million in Q2 2025 and $1.9 million in Q1 2025.